Zacks Investment Research upgraded shares of Chiasma (NASDAQ:CHMA) from a hold rating to a buy rating in a research report released on Monday, Zacks.com reports. Zacks Investment Research currently has $4.75 price target on the biotechnology company’s stock.

According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “

Other analysts have also recently issued research reports about the stock. Cantor Fitzgerald restated an overweight rating on shares of Chiasma in a research report on Tuesday, March 17th. HC Wainwright raised their price target on Chiasma from $10.00 to $11.00 and gave the company a buy rating in a research report on Monday, June 29th. Piper Sandler cut their price objective on Chiasma from $22.00 to $19.00 in a report on Tuesday, July 7th. Finally, BidaskClub upgraded Chiasma from a hold rating to a buy rating in a research report on Tuesday, June 23rd. Eight equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of Buy and an average target price of $12.75.

Shares of NASDAQ CHMA opened at $4.32 on Monday. The stock’s 50-day simple moving average is $5.91 and its two-hundred day simple moving average is $4.94. Chiasma has a twelve month low of $2.88 and a twelve month high of $9.25.

Chiasma (NASDAQ:CHMA) last posted its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.36) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.05). Research analysts forecast that Chiasma will post -1.35 EPS for the current fiscal year.

A number of institutional investors have recently made changes to their positions in the business. Vivo Capital LLC purchased a new position in Chiasma in the 1st quarter worth approximately $4,643,000. Ikarian Capital LLC grew its holdings in shares of Chiasma by 88.1% in the first quarter. Ikarian Capital LLC now owns 2,075,492 shares of the biotechnology company’s stock worth $7,576,000 after purchasing an additional 972,195 shares during the last quarter. Stonepine Capital Management LLC increased its stake in shares of Chiasma by 305.2% in the first quarter. Stonepine Capital Management LLC now owns 744,134 shares of the biotechnology company’s stock worth $2,716,000 after buying an additional 560,474 shares during the period. Rock Springs Capital Management LP increased its stake in shares of Chiasma by 16.4% in the first quarter. Rock Springs Capital Management LP now owns 1,350,000 shares of the biotechnology company’s stock worth $4,928,000 after buying an additional 190,000 shares during the period. Finally, State Street Corp raised its holdings in Chiasma by 11.6% during the 4th quarter. State Street Corp now owns 598,524 shares of the biotechnology company’s stock valued at $2,969,000 after buying an additional 62,049 shares during the last quarter. 75.21% of the stock is currently owned by institutional investors and hedge funds.

About Chiasma

Chiasma, Inc, a clinical late-stage biopharmaceutical company, focuses on developing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company develops oral octreotide capsules for adult patients under the MYCAPSSA name, which is in Phase III clinical trials for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone.

Read More: How can you know how many shares are floating?

Get a free copy of the Zacks research report on Chiasma (CHMA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Chiasma (NASDAQ:CHMA)

Receive News & Ratings for Chiasma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma and related companies with MarketBeat.com's FREE daily email newsletter.